Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Inventory (2020 - 2025)

Historic Inventory for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $51.6 million.

  • Cytek Biosciences' Inventory rose 1036.11% to $51.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.6 million, marking a year-over-year increase of 1036.11%. This contributed to the annual value of $43.9 million for FY2024, which is 2789.89% down from last year.
  • As of Q3 2025, Cytek Biosciences' Inventory stood at $51.6 million, which was up 1036.11% from $49.5 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Inventory ranged from a high of $69.5 million in Q1 2023 and a low of $26.7 million during Q2 2021
  • Its 5-year average for Inventory is $48.5 million, with a median of $48.8 million in 2022.
  • As far as peak fluctuations go, Cytek Biosciences' Inventory surged by 8298.67% in 2023, and later tumbled by 3001.87% in 2024.
  • Cytek Biosciences' Inventory (Quarter) stood at $32.2 million in 2021, then soared by 49.68% to $48.2 million in 2022, then grew by 26.42% to $60.9 million in 2023, then dropped by 27.9% to $43.9 million in 2024, then grew by 17.67% to $51.6 million in 2025.
  • Its Inventory was $51.6 million in Q3 2025, compared to $49.5 million in Q2 2025 and $45.3 million in Q1 2025.